Literature DB >> 1715165

Rapamycin: FK506's fraternal twin or distant cousin?

R E Morris1.   

Abstract

Rapamycin (RPM) is the latest in a series of new bacterial-derived immunosuppressants. Here, Randall Morris compares and contrasts the mechanism of action and immune-modulating potential of RPM with the structurally-similar FK506.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1715165     DOI： 10.1016/S0167-5699(05)80040-4

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


  11 in total

1.  A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients.

Authors:  R Shapiro; M L Jordan; V P Scantlebury; C Vivas; J J Fung; J McCauley; P Randhawa; A J Demetris; W Irish; A Jain
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

Review 2.  The changing face of liver transplantation.

Authors:  C Shorrock; J Neuberger
Journal:  Gut       Date:  1993-03       Impact factor: 23.059

Review 3.  Kidney transplantation in highly sensitized patients: reappraisal of etiology, evaluation, and management protocols.

Authors:  R Indudhara; R B Khauli
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

4.  Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice.

Authors:  W L Baeder; J Sredy; S N Sehgal; J Y Chang; L M Adams
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

5.  Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling.

Authors:  Valerie I Brown; Junjie Fang; Keith Alcorn; Rosalind Barr; Jenny M Kim; Robert Wasserman; Stephan A Grupp
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

Review 6.  Role of the BCR complex in B cell development, activation, and leukemic transformation.

Authors:  Susan R Rheingold; Valerie I Brown; Junjie Fang; Jenny M Kim; Stephan A Grupp
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

7.  Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins.

Authors:  N Terada; H R Patel; K Takase; K Kohno; A C Nairn; E W Gelfand
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

8.  Inhibition of the serine/threonine protein phosphatases PP1 and PP2A in lymphocytes: effect on mRNA levels for interleukin-2, IL-2R alpha, krox-24, p53, hsc70 and cyclophilin.

Authors:  F M Richards; J Milner; S Metcalfe
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

9.  Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors.

Authors:  Terry Furlong; Hans-Peter Kiem; Frederick R Appelbaum; Paul A Carpenter; H Joachim Deeg; Kristine Doney; Mary E D Flowers; Marco Mielcarek; Richard A Nash; Rainer Storb; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

10.  A prospective randomized trial of FK506-based immunosuppression after renal transplantation.

Authors:  R Shapiro; M L Jordan; V P Scantlebury; C Vivas; J J Fung; J McCauley; P Randhawa; A J Demetris; W Irish; S Mitchell
Journal:  Transplantation       Date:  1995-02-27       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.